Rifampicin and fluoroquinolone based therapy is generally considered as first-choice targeted oral antimicrobial therapy for staphylococcal prosthetic joint infections (PJI) treated with debridement, antibiotics and implant retention (DAIR). Alternative equally effective antimicrobial strategies are urgently needed due to toxicity and drug-drug interactions that frequently occur with this strategy. Data from recent clinical studies suggests equipoise for other antimicrobial treatment regimens. The objective of the The RiCOTTA-trial is a multicenter, non-inferiority, open-label, randomized controlled trial evaluating clindamycin versus rifampicin/fluoroquinolone combination therapy in the oral treatment phase in patients with staphylococcal PJI managed with DAIR. The trial is performed in 16 hospitals in the Netherlands. Eligible patients are adults with staphylococcal knee or hip PJI managed by DAIR. Patients are included one to six days before antibiotic treatment is switched from intravenous to oral therapy. Patients with a contraindication for rifampicin, with a megaprosthesis or who receive intravenous antibiotics for more than three weeks after initial debridement are excluded. Primary outcome is treatment success one year after finishing antimicrobial treatment. Success is defined as the absence of: i. Infection related re-surgery, ii. New episode of antibiotic treatment for infection of the index joint after the initial treatment phase of 12 weeks, iii. Ongoing use of antibiotics for the index joint at the end of follow-up, iv. Death. The estimated treatment success of rifampicin combination therapy is 85% and the monotherapy strategy is considered not inferior when the difference in treatment success will be less than 10%. Enrolment of 158 patients per group (316 in total) is needed to confirm non-inferiority of monotherapy with a power of 80%. The trial is currently open for enrolment. The study is approved by the Medical Ethics Committee Leiden, the Hague, Delft, the Netherlands and registered under EU trial number 2022-501620-26-00 in Clinical Trial Information System.Aim
Method
We evaluated the use of percutaneous screw epiphysiodesis to treat genu valgum deformity in adolescents, and the possibilities of extending its use to younger patients with different causes of angular deformities or leg length discrepancies. To date, the surgical options for adolescent idiopathic genu valgum have been medial physeal retardation by stapling, growth arrest by epiphysiodesis of the distal femur and/or tibia, or osteotomy. From September 1999, we prospectively studied 16 patients, 11 of whom had angular knee deformities (20 legs) and five limb length inequality. From a preoperative mean of 12.25( the tibiofemoral angle reduced to 6.4° at the latest assessment. Percutaneous epiphysiodesis using transphyseal screws proved to be a reliable method with few complications and the advantages of simplicity, short operating times, rapid postoperative rehabilitation and reversibility.
